Similar articles

• [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].

  Abasq C, Duval-Modeste AB, Courville P, Joly P. Abasq C, et al. Ann Dermatol Venereol. 2008 Jun-Jul;135(6-7):509-11. doi: 10.1016/j.annder.2008.02.018. Epub 2008 May 27. Ann Dermatol Venereol. 2008. PMID: 18598807 French. No abstract available.
• Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.

  Kyrtsonis MC, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, Antoniou C, Korkolopoulou P, Panayiotidis P, Pangalis GA. Kyrtsonis MC, et al. Eur J Haematol. 2006 Oct;77(4):300-3. doi: 10.1111/j.1600-0609.2006.00720.x. Epub 2006 Jul 19. Eur J Haematol. 2006. PMID: 16856917
• Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.

  Kerl K, Prins C, Saurat JH, French LE. Kerl K, et al. Br J Dermatol. 2006 Dec;155(6):1197-200. doi: 10.1111/j.1365-2133.2006.07523.x. Br J Dermatol. 2006. PMID: 17107389
• [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].

  Gamo R, Calzado L, Pinedo F, López-Estebaranz JL. Gamo R, et al. Actas Dermosifiliogr. 2008 May;99(4):291-6. Actas Dermosifiliogr. 2008. PMID: 18394405 Review. Spanish.
• Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.

  Seker M, Ustaalioğlu BB, Bilici A, Yildirim ME, Kefeli U, Barisik NO, Tamer I, Gumus M. Seker M, et al. Leuk Res. 2010 Jul;34(7):e160-3. doi: 10.1016/j.leukres.2010.02.013. Epub 2010 Mar 12. Leuk Res. 2010. PMID: 20219245 Review. No abstract available.